Subtype
Malignant Mediastinal Neoplasm
CI-CAN-00001141Explore in graph →
64 active trials1 approved drugs
- NCIt
- C3549
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001141Explore in graph →
Clinical trials
144 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06339255 |
| Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) |
| recruiting |
| — |
| 5,300 |
| Paolo CorradiniOTHER |
| 1 |
| Apr 1, 2024 |
| clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT05130489 | CAR T Cell Therapy Related Cardiovascular Outcomes(CARTCO) | completed | — | 150 | University College London HospitalsOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03019666 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | completed | Phase 1 | 39 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02950220 | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 2 | Kami MaddocksOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02769299 | Cardiotoxicity of Radiation Therapy (CTRT) | completed | — | 147 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00944567 | A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma | completed | — | 125 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Aug 15, 2017 | clinicaltrials |
| NCT02423291 | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL(FIL_SGN01) | completed | Phase 2 | 15 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(S-BR) | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT03037177 | Mediastinal Grey Zone Lymphoma From the LYSA | completed | — | 99 | Hospices Civils de LyonOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Medivation, Inc.INDUSTRY | 1 | Nov 25, 2016 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
| NCT00003941 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer | completed | Phase 3 | 222 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 24, 2012 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2024source: clinicaltrials